| Code | CSB-RA008545MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to batoclimab, targeting the neonatal Fc receptor (FCGRT, FcRn). FCGRT plays a critical role in antibody homeostasis by binding to the Fc region of IgG antibodies at acidic pH within endosomes, thereby rescuing them from lysosomal degradation and recycling them back to circulation or transcytosing them across cellular barriers. This receptor-mediated recycling mechanism is responsible for maintaining the extended half-life of IgG antibodies in serum and facilitating maternal-fetal antibody transfer. Dysregulation of FCGRT function is implicated in various autoimmune conditions where pathogenic autoantibodies contribute to disease pathology, including myasthenia gravis, immune thrombocytopenia, and pemphigus.
Batoclimab is a fully humanized monoclonal antibody that blocks the interaction between FCGRT and IgG, promoting the degradation of circulating antibodies including pathogenic autoantibodies. This biosimilar antibody provides researchers with a valuable tool for investigating FCGRT biology, IgG homeostasis mechanisms, and antibody-mediated autoimmune disease processes. It supports studies exploring therapeutic strategies for conditions characterized by harmful autoantibody production.
There are currently no reviews for this product.